Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
2 sources·Updated September 12, 2026
Covered by 2 sources
- News-Medical·15h agoSubcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the…
Read at News-Medical → - Medical Xpress·18h agoSubcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the…
Read at Medical Xpress →
